Clinical Trial Update: Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating apatinib mesylate in combination with doxorubicin and ifosfamide for advanced soft-tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Doxorubicin (doxorubicin)
• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: UNKNOWN